Health & Medicinearticle2026-10-22

Ketamine Versus Electroconvulsive Therapy for Nonpsychotic Treatment-Resistant Depression: A Cost-Effectiveness Analysis

0 citations

Abstract

Electroconvulsive therapy (ECT) is a highly effective intervention for treatment-resistant depression; however, its use has been limited partly because of concerns about cognitive side effects. Evidence for the sustained (>1 month) efficacy of ketamine versus ECT for treatment-resistant depression has only recently been demonstrated. This study aimed to examine the cost-effectiveness—that is, the costs and benefits measured as quality-adjusted life-years (QALYs)—of racemic ketamine versus that of ECT for treatment-resistant depression.

// Source

View paper (DOI)OpenAlexPsychiatric ServicesPublished 2026-10-22

Authors: Michael Lebenbaum, Benoit H. Mulsant, Sagar V. Parikh, Jason Fletcher, Jeffrey S. Hoch, Paul Kurdyak, Daniel M. Blumberger, Amit Anand, Manish Jha, Venkat Bhat

Institutions: University of Michigan, University of Toronto, University of Wisconsin–Madison, St. Michael's Hospital, Southwestern Medical Center, The University of Texas Southwestern Medical Center, University of California, Davis, Centre for Addiction and Mental Health, Mass General Brigham, Department of Public Health, Wisconsin Department of Health Services